Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Hansa Biopharma AB (publ)    HNSA   SE0002148817

HANSA BIOPHARMA AB (PUBL)

(HNSA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Stockholm
11/25/2020 11/26/2020 11/27/2020 11/30/2020 12/01/2020 Date
232.6(c) 233(c) 243(c) 250.8(c) 246.6(c) Last
329 643 167 414 204 482 928 303 197 616 Volume
+5.44% +0.17% +4.29% +3.21% -1.67% Change
More quotes
Financials
Sales 2020 52,1 M 6,15 M 6,15 M
Net income 2020 -368 M -43,4 M -43,4 M
Net cash position 2020 1 396 M 165 M 165 M
P/E ratio 2020 -26,4x
Yield 2020 -
Sales 2021 107 M 12,6 M 12,6 M
Net income 2021 -508 M -59,8 M -59,8 M
Net cash position 2021 818 M 96,4 M 96,4 M
P/E ratio 2021 -21,6x
Yield 2021 -
Capitalization 10 967 M 1 291 M 1 293 M
EV / Sales 2020 184x
EV / Sales 2021 94,7x
Nbr of Employees 80
Free-Float 95,9%
More Financials
Company
Hansa Biopharma AB, formerly Hansa Medical AB, is a Sweden-based biopharmaceutical company with focus on immunomodulatory enzymes for treatment and prevention of rare and severe autoimmune conditions and transplant rejection. The Company’s operations consist of research and development for drug discovery. The Company conducts several projects, among which primary are IdeS (Immunoglobulin G-degrading enzyme of... 
More about the company
Notations Surperformance© of Hansa Biopharma AB (publ)
Trading Rating : Investor Rating :
More Ratings
All news about HANSA BIOPHARMA AB (PUBL)
11/02HANSA BIOPHARMA : Nomination Committee formed
AQ
10/22Hansa Biopharma interim report Jan-Sep 2020
AQ
09/24HANSA BIOPHARMA : Biopharm announces positive high-level data from investigator-..
PU
09/24HANSA BIOPHARMA : Biopharm announces positive high-level data from investigator-..
AQ
09/17HANSA BIOPHARMA :  Biopharma to host Capital Markets Day on Thursday October 29,..
PU
09/17HANSA BIOPHARMA :  Biopharma to host Capital Markets Day on Thursday October 29,..
AQ
09/11HANSA BIOPHARMA : certified as a Great Place to Work
AQ
09/01HANSA BIOPHARMA : provides updated guidance on its clinical programs
AQ
08/31HANSA BIOPHARMA : announces participation in Fall conferences and an updated fin..
AQ
08/26HANSA BIOPHARMA : ­Sale of shares in Hansa Biopharma AB (publ)
AQ
08/26HANSA BIOPHARMA : The EU Commission grants conditional approval for Idefirix (im..
AQ
08/26HANSA BIOPHARMA : Nexttobe announces its intention to sell shares in Hansa Bioph..
AQ
07/31HANSA BIOPHARMA PUBL : announces increase in number of shares and votes
AQ
07/16HANSA BIOPHARMA PUBL : expands the leadership team with the appointment of Katja..
AQ
07/16Hansa Biopharma interim report Jan-Jun 2020
AQ
More news
News in other languages on HANSA BIOPHARMA AB (PUBL)
10/1410 Biotechs qui font parler d'elles
03/30HANSA BIOPHARMA AB (PUBL) : publication des résultats annuels
03/30HANSA BIOPHARMA AB (PUBL) : Veröffentlichung des Jahresergebnisses
2019HANSA BIOPHARMA AB (PUBL) : mauvaise nouvelle pour la biotech suédoise
More news
Chart HANSA BIOPHARMA AB (PUBL)
Duration : Period :
Hansa Biopharma AB (publ) Technical Analysis Chart | HNSA | SE0002148817 | MarketScreener
Technical analysis trends HANSA BIOPHARMA AB (PUBL)
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 2
Average target price 238,50 SEK
Last Close Price 246,60 SEK
Spread / Highest target 16,4%
Spread / Average Target -3,28%
Spread / Lowest Target -23,0%
EPS Revisions
Managers
NameTitle
Søren Tulstrup President & Chief Executive Officer
Ulf Arne Wiinberg Chairman
Christian Kjellman Chief Operating & Scientific Officer
Donato Spota Chief Financial Officer
Achim Kaufhold Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
HANSA BIOPHARMA AB (PUBL)199.11%1 303
MODERNA, INC.680.88%60 441
LONZA GROUP AG61.27%46 692
CELLTRION, INC.87.85%41 055
IQVIA HOLDINGS INC.9.37%32 400
SEAGEN INC.49.05%30 708